Impact of the COVID-19 Pandemic in Gynecological Oncology

NCT04351139CompletedOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Hospices Civils de Lyon

Enrollment

205

Start Date

2020-05-06

Completion Date

2020-11-30

Study Type

OBSERVATIONAL

Official Title

Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology

Interventions

modification of the planned therapeutic management

Conditions

Gynecologic CancerBreast Neoplasm FemaleUterine NeoplasmsOvarian NeoplasmsUterine Cervical NeoplasmsVulvar NeoplasmsVaginal Neoplasms

Eligibility

Age Range

18 Years+

Sex

FEMALE

Inclusion Criteria:

* women over 18
* gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer)
* therapeutic management planned during quarantine
* person having expressed his non-opposition

Inclusion Criteria of control group :

* women over 18
* gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer)
* therapeutic management planned on the end of the year 2019
* person having expressed his non-opposition

Exclusion Criteria:

* inability to understand the information given
* person deprived of liberty,
* person under guardianship.

Outcome Measures

Primary Outcomes

percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)

modification of the planned therapeutic management

Time frame: Day O

Locations

Service de Gynécologie, HFME, Hospices Civils de Lyon, Bron, France

Service de Gynécologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France

Service Gynécologie, CHLS, Hospices Civils de Lyon, Pierre-Bénite, France